Clinical Paper: Effects of an Extensively Hydrolyzed Formula Supplemented with Two Human Milk Oligosaccharides

In a randomised clinical trial by Vandenplas et al. 2022, using an extensively hydrolyzed formula (EHF) supplemented with two human milk oligosaccharides (HMO) in infants with cow’s milk protein allergy (CMPA), it demonstrated a reduction in frequency of upper respiratory tract infections and a lower incidence of ear infections at 12 months as well as supporting normal growth in infants with CMPA.